Lamotrigine
- Generic Name
- Lamotrigine
- Brand Names
- Lamictal
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7Cl2N5
- CAS Number
- 84057-84-1
- Unique Ingredient Identifier
- U3H27498KS
- Background
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...
- Indication
Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...
- Associated Conditions
- Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
- Associated Therapies
- Conversion to monotherapy
WEUSKOP6166: Lamotrigine and Aseptic Meningitis
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01657864
Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT01618825
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition
- Conditions
- Interventions
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT01618799
- Locations
- 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India
Lamotrigine Phase III Study in Bipolar I Disorder
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 265
- Registration Number
- NCT01602510
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Sequential Multiple Assignment Treatment for Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2020-08-19
- Target Recruit Count
- 112
- Registration Number
- NCT01588457
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸University of Texas Health Science Center, San Antonio, Texas, United States
Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 20
- Registration Number
- NCT01513720
- Locations
- 🇺🇸
AAI Clinic, Quadrangle drive, North Carolina, United States
Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 20
- Registration Number
- NCT01513681
- Locations
- 🇺🇸
AAI Clinic, Quadrangle drive, North Carolina, United States
Decision-Making in Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Emory University
- Target Recruit Count
- 37
- Registration Number
- NCT01463111
- Locations
- 🇺🇸
Emory University Mood and Anxiety Disorders Program, Atlanta, Georgia, United States
Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01431976
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT01431963
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.